

5251 '01 MAR 16 P3:46

Linda Van Den Bussche
5306 North Magnet Avenue
Chicago, IL 60630

March 13, 2001

U.S. Food and Drug Administration
Dockets Management Branch
5630 Fishers Lane, Room 1061; HFA-305
Rockville, MD 20852


Docket number 00N-0989.

This proposal only brings gene therapy and xenotransplantation in compliance with the same types of information already released to the public by other government agencies. Because of grave public health risks, disclosure should include additional information such as physicians, medical centers, and so on-make public all information except trade secrets and patient identification.

The FDA must assume the sole responsibility for summarizing and distributing information submitted by the research sponsor, rather than leave it to the sponsor's discretion.

Because of the public health risks, ethical issues, cost uncertainty, and the inability to adequately assess other alternatives, all xenotransplantation clinical trials should stop.

Thank You,



Linda Van Den Bussche

00N-0989

C15



Mrs. Linda Van Den Bussche
5306 N. Magnet Ave.
Chicago, IL 60630-1216



U.S. Food and Drug Administration
Dockets Management Branch
5630 Fishers Lane, Room 1061; HFA-305
Rockville, MD 20852

20857/0001